Cargando…

Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study

BACKGROUND: Patients with Mycobacterium avium complex (MAC) lung disease (LD) have a heterogeneous prognosis. This study aimed to develop and validate a prognostic scoring model for these patients using independent risk factors for survival. METHODS: We retrospectively analyzed the data of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Shogo, Ito, Akihiro, Hashimoto, Toru, Marumo, Satoshi, Tokumasu, Hironobu, Kotani, Aya, Yamaki, Haruka, Shirata, Masahiro, Furuuchi, Koji, Fukui, Motonari, Ishida, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477133/
https://www.ncbi.nlm.nih.gov/pubmed/28629426
http://dx.doi.org/10.1186/s12879-017-2544-0
_version_ 1783244732163424256
author Kumagai, Shogo
Ito, Akihiro
Hashimoto, Toru
Marumo, Satoshi
Tokumasu, Hironobu
Kotani, Aya
Yamaki, Haruka
Shirata, Masahiro
Furuuchi, Koji
Fukui, Motonari
Ishida, Tadashi
author_facet Kumagai, Shogo
Ito, Akihiro
Hashimoto, Toru
Marumo, Satoshi
Tokumasu, Hironobu
Kotani, Aya
Yamaki, Haruka
Shirata, Masahiro
Furuuchi, Koji
Fukui, Motonari
Ishida, Tadashi
author_sort Kumagai, Shogo
collection PubMed
description BACKGROUND: Patients with Mycobacterium avium complex (MAC) lung disease (LD) have a heterogeneous prognosis. This study aimed to develop and validate a prognostic scoring model for these patients using independent risk factors for survival. METHODS: We retrospectively analyzed the data of patients with MAC-LD from two hospitals (cohort 1, n = 368; cohort 2, n = 118). Cohort 1 was evaluated using a multivariate Cox proportional hazards model to identify independent risk factors for overall survival (OS). A prognostic scoring model composed of these factors was developed, and cohort 1 was stratified into three groups according to risk using the log-rank test. Finally, the prognostic scoring model was validated using the data of cohort 2. RESULTS: Seven independent risk factors for OS were selected from cohort 1, including the male sex, age ≥ 70 years, the presence of a malignancy, body mass index <18.5 kg/m(2), lymphocyte count <1000 cells/μL, serum albumin levels <3.5 g/dL, and fibrocavitary disease. The areas under the receiver operating characteristic curves for the prognostic scoring model were 0.84 [95% confidence interval (CI), 0.80 − 0.89] for cohort 1 and 0.84 (95% CI, 0.75 − 0.92) for cohort 2. The 5-year OS rates of patients stratified into low-risk, intermediate-risk, and high-risk groups were 97.6, 76.6, and 30.8%, respectively (P < 0.001), in cohort 1, and 97.2, 82.3, and 45.4%, respectively (P < 0.001), in cohort 2. CONCLUSIONS: This study is the first to develop and validate a prognostic scoring model for patients with MAC-LD. This model may prove useful in clinical settings and practical in estimating the prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2544-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5477133
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54771332017-06-22 Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study Kumagai, Shogo Ito, Akihiro Hashimoto, Toru Marumo, Satoshi Tokumasu, Hironobu Kotani, Aya Yamaki, Haruka Shirata, Masahiro Furuuchi, Koji Fukui, Motonari Ishida, Tadashi BMC Infect Dis Research Article BACKGROUND: Patients with Mycobacterium avium complex (MAC) lung disease (LD) have a heterogeneous prognosis. This study aimed to develop and validate a prognostic scoring model for these patients using independent risk factors for survival. METHODS: We retrospectively analyzed the data of patients with MAC-LD from two hospitals (cohort 1, n = 368; cohort 2, n = 118). Cohort 1 was evaluated using a multivariate Cox proportional hazards model to identify independent risk factors for overall survival (OS). A prognostic scoring model composed of these factors was developed, and cohort 1 was stratified into three groups according to risk using the log-rank test. Finally, the prognostic scoring model was validated using the data of cohort 2. RESULTS: Seven independent risk factors for OS were selected from cohort 1, including the male sex, age ≥ 70 years, the presence of a malignancy, body mass index <18.5 kg/m(2), lymphocyte count <1000 cells/μL, serum albumin levels <3.5 g/dL, and fibrocavitary disease. The areas under the receiver operating characteristic curves for the prognostic scoring model were 0.84 [95% confidence interval (CI), 0.80 − 0.89] for cohort 1 and 0.84 (95% CI, 0.75 − 0.92) for cohort 2. The 5-year OS rates of patients stratified into low-risk, intermediate-risk, and high-risk groups were 97.6, 76.6, and 30.8%, respectively (P < 0.001), in cohort 1, and 97.2, 82.3, and 45.4%, respectively (P < 0.001), in cohort 2. CONCLUSIONS: This study is the first to develop and validate a prognostic scoring model for patients with MAC-LD. This model may prove useful in clinical settings and practical in estimating the prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2544-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-19 /pmc/articles/PMC5477133/ /pubmed/28629426 http://dx.doi.org/10.1186/s12879-017-2544-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kumagai, Shogo
Ito, Akihiro
Hashimoto, Toru
Marumo, Satoshi
Tokumasu, Hironobu
Kotani, Aya
Yamaki, Haruka
Shirata, Masahiro
Furuuchi, Koji
Fukui, Motonari
Ishida, Tadashi
Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title_full Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title_fullStr Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title_full_unstemmed Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title_short Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
title_sort development and validation of a prognostic scoring model for mycobacterium avium complex lung disease: an observational cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477133/
https://www.ncbi.nlm.nih.gov/pubmed/28629426
http://dx.doi.org/10.1186/s12879-017-2544-0
work_keys_str_mv AT kumagaishogo developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT itoakihiro developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT hashimototoru developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT marumosatoshi developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT tokumasuhironobu developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT kotaniaya developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT yamakiharuka developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT shiratamasahiro developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT furuuchikoji developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT fukuimotonari developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy
AT ishidatadashi developmentandvalidationofaprognosticscoringmodelformycobacteriumaviumcomplexlungdiseaseanobservationalcohortstudy